Participation in the Eastern Cooperative Oncology Group

参加东部肿瘤合作组

• 批准号: 8699962
• 负责人: JOSEPH AISNER
• 金额: $ 16万
• 依托单位: RBHS -CANCER INSTITUTE OF NEW JERSEY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-02 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8699962
• 关键词: Antibodies; BCL2 gene; Basic Science; Cancer Institute of New Jersey; Chemoprevention; Chest; Clinic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Data; Data Quality; Dentistry; Development; Disease; Eastern Cooperative Oncology Group; Esophageal; Evaluation; Faculty; Failure; Fostering; Genetic Polymorphism; Grant; Green tea; Hospitals; Institution; Laboratories; Lesion; Link; Malignant neoplasm of prostate; Medicine; Modality; New Agents; New Brunswick; New Jersey; Nurses; Operative Surgical Procedures; Paraffin; Patient Monitoring; Patients; Peer Review; Pharmacists; Phase; Physicians; Pilot Projects; Premalignant; Prevention; Protocol Compliance; Protocols documentation; Publishing; Radiation therapy; Recombinant Vaccines; Research Personnel; Resistance; Resources; Science; Selenium; Site; Source; Specialist; Specimen; Testing; Universities; Wood material; Work; base; chemotherapy; design; human ABCG2 protein; interest; medical schools; member; oncology; phase 1 study; phase 2 study; programs; symptom management

DESCRIPTION (provided by applicant): CINJ, an ECOG member institution since 1994, continues to grow as an active and important site for ECOG studies. The CINJ disease specific multi-modality clinics are ideally suited for development, implementation, and participation in ECOG science, trials, and administration. CINJ main member and affiliate accrual to ECOG sponsored or endorsed clinical trials continues to grow. CINJ faculty actively participate in multiple ECOG committees, and 12 faculty participate in 13 committees, 2 as chair and 2 as vice-chairs. CINJ is a phase I U10 holder, and operates a strong phase I program, which serves as a potential resource for group studies, and several ECOG studies were first piloted at CINJ. CINJ faculty also have a growing participation in group science and 13 studies were developed, activated, or chaired by 6 CINJ faculty and include 3 thoracic studies, 7 GU studies, 2 Gl studies, and 1 chemoprevention study. Others are also in development. CINJ investigators were instrumental in bringing recombinant vaccine trials to prostate cancer, and further such trials are in development. CINJ lab investigators also participate in ECOG studies with the correlative sciences projects. For example correlative science projects tested bcl-2 modulation of resistance, and breast cancer resistance protein polymorphisms SCLC are under analysis. Another project is linked to the selenium chemoprevention trial and evaluates the impact of various IHC and FISH markers in surgical specimens. CINJ is an ECOG Prevention Center, and several of our faculty participate in the Prevention Committee activities. Despite the failure of the green tea study to launch, another study from CINJ proposes to test a unique antibody in paraffin sections to distinguish Barrett's pre-malignant esophageal lesions as a candidate source for chemoprevention. CINJ also became a member of the ECOG Symptom Management Consortium: one physician, one pharmacist and several nurses are actively working in this consortium to activate trials We propose to use this grant to: 1) continue our strong ECOG committee participations; 2) design and participate in ECOG multi-modality studies; 3) engage our peer-reviewed institutional laboratories as potential sources for group science; 4) foster continued accrual from CINJ and from our broad network of affiliated institutions; 5) monitor patient entry, protocol compliance, and data quality; 6) submit timely data forms; 7) continue to develop pilot studies with other ECOG members of interest to ECOG; and 8) enhance the interaction of our basic science laboratories and the group's clinical trials programs.

描述（由申请人提供）：CINJ自1994年以来一直是ECOG的成员机构，并继续发展成为ECOG研究的活跃和重要研究中心。CINJ疾病特异性多模式诊所非常适合开发，实施和参与ECOG科学，试验和管理。CINJ主要成员和附属机构对ECOG申办或批准的临床试验的累积持续增长。CINJ教师积极参与多个ECOG委员会，12名教师参加13个委员会，2名担任主席，2名担任副主席。CINJ是I期U10保持器持有者，并实施了一项强大的I期项目，该项目可作为群体研究的潜在资源，并且几项ECOG研究首次在CINJ进行试点。CINJ教师也越来越多地参与群体科学，13项研究由6名CINJ教师开发，激活或主持，包括3项胸部研究，7项GU研究，2项GI研究和1项化学预防研究。其他的也在开发中。CINJ研究人员在将重组疫苗试验用于前列腺癌方面发挥了重要作用，进一步的此类试验正在开发中。CINJ实验室研究人员还参与了相关科学项目的ECOG研究。如相关科研项目检测bcl-2对耐药的调节作用，乳腺癌耐药蛋白多态性SCLC正在研究中。另一个项目与硒化学预防试验有关，并评估了手术标本中各种IHC和FISH标记物的影响。CINJ是一个ECOG预防中心，我们的几个教师参加预防委员会的活动。尽管绿色茶研究未能启动，CINJ的另一项研究提出在石蜡切片中测试一种独特的抗体，以区分巴雷特癌前食管病变作为化学预防的候选来源。CINJ还成为ECOG症状管理联盟的成员：一名医生，一名药剂师和几名护士正在积极参与该联盟的工作，以激活试验。我们建议使用这笔资金：1）继续我们强大的ECOG委员会参与; 2）设计和参与ECOG多模态研究; 3）聘请我们的同行评审机构实验室作为群体科学的潜在来源; 4）促进CINJ和我们广泛的附属机构网络的持续积累; 5）监测患者入组、方案依从性和数据质量; 6）及时提交数据表; 7）继续与ECOG感兴趣的其他ECOG成员开展试点研究; 8）加强我们的基础科学实验室和该集团临床试验项目的互动。